CriticalMacrolide antibiotic×Highly selective α1A-adrenergic blocker
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises silodosin, and alcohol dehydrogenase and the enzyme UGT2B7 also take part. Silodosin is a substrate of the transporter P-glycoprotein (P-gp). Substances that inhibit these enzymes and transporters can change the levels of silodosin and its active metabolite (silodosin summary of product characteristics, SmPC, European Medicines Agency, EMA). The Spanish clarithromycin SmPC classes clarithromycin as a strong CYP3A4 inhibitor and states that it inhibits P-gp (clarithromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The pair has not been studied, but ketoconazole 400 mg, another strong CYP3A4 inhibitor, increased the peak concentration of silodosin 3.7-fold and the area under the concentration curve (AUC) 3.1-fold (EMA). The US silodosin label names clarithromycin among the strong CYP3A4 inhibitors that are contraindicated with silodosin (silodosin label, US Food and Drug Administration, FDA). In a QT study, a silodosin dose of 24 mg was used to model worst-case exposure, for example with strong CYP3A4 inhibitors, and no QTc prolongation occurred (FDA).
Symptoms
In healthy men taking up to 48 mg of silodosin a day, the dose-limiting adverse reaction was a drop in blood pressure when standing up (silodosin summary of product characteristics, SmPC, European Medicines Agency, EMA). Such a drop causes dizziness and, rarely, fainting. The adverse reactions of silodosin also include a fast heart rate and palpitations (EMA). A drop in blood pressure when standing up may occur as soon as silodosin is started, and, as with other alpha-blockers, there is a risk of fainting (silodosin label, US Food and Drug Administration, FDA). The most common adverse effects of silodosin are ejaculation disorders, such as retrograde ejaculation and reduced or absent ejaculate, in about 23% of men (EMA).
Management
The US silodosin label contraindicates the combination. It names clarithromycin among the strong inhibitors of the enzyme CYP3A4 that must not be taken with silodosin (silodosin label, US Food and Drug Administration, FDA). The European silodosin summary of product characteristics (SmPC) does not recommend silodosin with strong CYP3A4 inhibitors, and the Spanish clarithromycin SmPC itself classes clarithromycin as one (silodosin SmPC, European Medicines Agency, EMA, and clarithromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The clarithromycin documents do not name silodosin. They say to use clarithromycin with caution with drugs metabolised mainly by CYP3A, to consider dose adjustments and, where possible, to monitor their levels (clarithromycin SmPC, AEMPS). So, during a clarithromycin course, choose another antibiotic or pause silodosin (this follows from the contraindication). The documents do not say when silodosin can be restarted after clarithromycin. The half-life of clarithromycin ranges from 2–4 hours to 5 hours, depending on the dose (clarithromycin SmPC, AEMPS). At the first signs of postural hypotension, such as dizziness, the patient should sit or lie down until the symptoms pass (silodosin SmPC, EMA). When starting silodosin, warn the patient about driving and operating machinery (silodosin FDA label). If a silodosin overdose causes hypotension, lay the patient supine, consider intravenous fluids if this is not enough, then vasopressors if needed, and monitor kidney function. Dialysis is unlikely to help (silodosin FDA label and SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Claritromicina, Klacid 500 mg (nº registro 60515) (2024)– AEMPS, CIMA, nº registro 60515 (Klacid 500 mg comprimidos recubiertos con película), revisión 10/2024, secciones 4.3, 4.4 y 4.5
- FDA: Silodosin capsules (silodosin) prescribing information (2026)– FDA, DailyMed setid ee8d577e-948d-4164-9671-c876544ac83b (Novadoz Pharmaceuticals, MSN Laboratories), versión 3, revisión 06/2026, secciones 4, 5.1, 5.4, 7.1 y 12.2; la sección 4 coincide con la de RAPAFLO (setid 96425d91-cfe1-477d-a130-b58c330ca8a3, 02/2012)
- EMA: Ficha técnica: Silodosina – Urorec (EU/1/09/608), sección 4.5 (2026)– EMA, Urorec 8 mg cápsulas duras (Recordati, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 09608011, consultada 16.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 4.8 y 4.9